GoodNewsoftheDay

True, recent, well-sourced good news, every morning.

HealthApprovedOpen licence1 min read

FDA approves Drug to help infants with rare disease live longer

The U.S. Food and Drug Administration approved Lembaz injection today to help patients with infantile-onset Niemann-Pick disease type C live longer.

This new therapy marks the first treatment shown to reduce death risk for people weighing at least seven kilograms. Eligible patients must have had symptoms start before reaching age six years old previously. Earlier approved options did not offer this specific life-extending benefit to those most affected by the condition.

Doctors administer Lembaz as an intrathecal injection directly into the spinal canal every two weeks. The procedure requires a trained healthcare provider to deliver the medication directly to the central nervous system.

Analysis of thirty-six patients treated with Lembaz showed longer overall survival compared to a matched external control group. The treated group experienced a 55% reduction in death risk during the clinical studies. Median survival time reached eight point five years versus four point nine years in controls.

Common side effects include hearing problems, balance issues, tiredness, sickness, stomach pain, pain in the head, high temperature, loose stools, sickness in the stomach, and coughing. Patients require comprehensive hearing evaluations before starting therapy and regularly throughout the course to monitor risks.

“For the first time, there is a treatment shown to help adults and children with this serious disease live longer”

Acting FDA Commissioner Kyle Diamantas

More health news

HealthLarge human trial1 min read

New weight-loss drug halves knee pain in trials

Two major clinical trials show a new weight-loss drug significantly reduces knee pain for patients with osteoarthritis.

· via ScienceDaily: Top Health

HealthLarge human trial1 min read

New pill offers hope for pancreatic cancer patients

A new drug called daraxonrasib has shown promise in reducing tumour size for people with advanced pancreatic cancer during a recent medical trial.

· via The Guardian: Science